CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant
Open Access
- 1 May 2012
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (20) , 16499-16509
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)Journal of Biological Chemistry, 2011
- Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 StrainsAntimicrobial Agents and Chemotherapy, 2011
- Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in ChinaJournal of Biological Chemistry, 2011
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide AntagonistsScience, 2010
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences, 2008
- Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4Science, 2007
- The SWISS-MODEL workspace: a web-based environment for protein structure homology modellingBioinformatics, 2005